利奈唑胺治疗重症肺炎的临床疗效及安全性研究.doc

利奈唑胺治疗重症肺炎的临床疗效及安全性研究

摘要：为了更加全面深入地了解利奈唑胺医治重症肺炎病人的医用价值，回顾性搜集莆田学院附属医院的重症监护科78例病患资料，时间是2012年3月1日到2013年3月1日的病患资料，并且将病患资料随机分成两组：利奈唑胺治疗组和万古霉素对照组都是39例，观察分析两组病患的治疗情况。从数据统计的结果中得知用利奈唑胺治疗的病人病情开始改善的有效率是69.3%（27/39)、细菌清除率是58.1%（18/31）;用万古霉素治疗的病人病情开始改善的有效率是64.1（25/39）、细菌清除率53.3（16/30）,l,两个不同组的数据的差异都没有统计学意义，但是利奈唑胺病人应用药物后有17.9%（7/39）的病患出现不良反应，而万古霉素病人应用药物后甚至超过33.3(13/39)，两个数据的差异有统计学意义。分析两组治疗病患的身体病症变化情况可以发现利奈唑胺治疗G+菌引起的重症肺炎的价值性更高，而且安全性更加的广泛。
关键词：疗效；利奈唑胺；不良反应；
Study on clinical efficacy and safety of linezolid in the treatment of severe pneumonia
Abstract: For a more thorough understanding of medical value of linezolid in treatment of patients with severe pneumonia, the intensive care department of Affiliated Hospital of Putian College were collected retrospectively 78 cases of patient data, time is March 1, 2012 to March 1, 2013 patients, and the patients were randomly divided into two groups: linezolid and vancomycin treatment group control group is 39 cases, observation of the two groups of patients treatment. From the statistical results that the efficient use of linezolid in the treatment of the patient began to improve is 69.3% ( 27\/39 ), the bacterial clearance rate was 58.1% ( 18\/31 ); 64.1 is the effective rate of vancomycin in the treatment of patients condition began to improve ( 25\/39 ), bacterial clearance rate was 53.3 ( 16\/30 ), L, differences between the two different groups of data are not statistically significant, but there are 17.9% linezolid patients using drugs ( 7\/39 ) in patients with adverse reactions, and vancomycin patients using drugs or even more than 33.3 ( 13\/39 ), the difference was statistically significant two data. Analysis of physical symptoms of treatment in the two groups patients can be found by value of linezolid in the treatment of severe pneumonia in G+ bacteria is higher, and safety is more widely.
Keywords: efficacy;linezolid; adverse reaction;